RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Makes additional investment in Series C extension of Numab Therapeutics, a Swiss clinical stage biotech company focused on the development of multi-specific antibodies in immunology and oncology. Numab’s fr.50 million, or $54.5 million, extension, brought its total Series C funding to fr.180 million. Funds will be used to support its clinical development efforts. RTW Biotech first invested in Numab in May 2021.

Roderick Wong, managing partner & chief information officer at RTW Investments, says: ‘We are delighted to continue supporting Numab Therapeutics. Their innovative approach to developing multi-specific antibodies is particularly promising, and we believe that their groundbreaking research and development efforts hold great potential for transforming autoimmune and cancer treatments. Following [Johnson & Johnson’s] announcement last summer to acquire Numab subsidiary, Yellow Jersey Therapeutics, we are optimistic that our continued partnership and this latest financing round will contribute to other significant advancements in immunology and oncology therapeutics.’

Current stock price: $1.40

12-month change: down 0.3%

Copyright 2025 Alliance News Ltd. All Rights Reserved.